Bobby Abreu worked out for the Red Sox in Venezuela recently, according to Alex Speier of WEEI.com.
Speier also notes that they had Abreu do some reps at first base, where the 38-year-old has never played even an inning in 17 big-league seasons.
Mike Napoli’s three-year, $39 million deal with the Red Sox remains unsigned, but even if that somehow falls apart it’d be a pretty big stretch to think they viewed Abreu as an actual fallback plan there.
As a potential bench bat, though, he still has some value thanks to strong on-base skills. Last season Abreu hit .242 with a .350 on-base percentage in 100 games for the Angels and Dodgers, and he’s posted an OBP above .350 in 15 consecutive seasons.
The Angels signed Japanese superstar Shohei Ohtani for a $2.3 million signing bonus last weekend. They may have damaged goods on their hands. Jeff Passan of Yahoo Sports reports that Ohtani underwent a physical that revealed a first-degree sprain of his ulnar collateral ligament. As a result, he got a platelet-rich plasma injection on October 20. This was made known to teams after Ohtani entered MLB’s posting system, so it wasn’t like the Angels went into this blind.
Ohtani’s report said, “Although partial damage of UCL in deep layer of his right UCL exists, he is able to continue full baseball participation with sufficient elbow care program.” It also said Ohtani “will most likely be available to start his throwing program approximately a month from the PRP.”
Passan notes that the report also mentioned that a “small free body” floats in Ohtani’s elbow near his UCL.
Ohtani isn’t without other injuries. He battled hamstring and ankle issues throughout 2017 and underwent right ankle surgery back in October. Thankfully for the Angels, this diagnosis is about as good as it could be considering the circumstances. However, if Ohtani does exacerbate his UCL issue, he may ultimately need Tommy John surgery at some point, which would take him out of action for at least a year.